Market News & Trends
Recipharm & Honeywell to Speed Development of Inhalers With Near-Zero Global Warming Potential Propellant
Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care….
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 Clinical Trial of Ninerafaxstat in Patients With Stable Angina
Imbria Pharmaceuticals, Inc. recently announced it has completed enrollment in the IMPROVE-ISCHEMIA Phase 2 placebo-controlled clinical trial of the investigational therapy, ninerafaxstat, in patients with…
BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer
BriaCell Therapeutics Corp. recently announced the National Cancer Institute (NCI), the US federal government's principal agency for cancer research and training, has awarded the company…
Avidity Biosciences Receives FDA Orphan Drug Designation for for Treatment of Duchenne Muscular Dystrophy in People With Mutations Amenable to Exon 44 Skipping
Avidity Biosciences, Inc. recently announced the US FDA has granted Orphan Drug designation to AOC 1044, the company's investigational therapy in development for the treatment…
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Tiziana Life Sciences Ltd. recently announced the US FDA has cleared the IND application for intranasal foralumab to be studied in Alzheimer’s disease. Foralumab could be a potentially….
Biostax Corp Announces FDA Acceptance of Three Investigational New Drug Applications Transfers for JKB-122 for the Treatment of NASH, NAFLD, and AIH
Immune Therapeutics, Inc. d/b/a Biostax Corp. recently announced it has accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-122,…
BioCorRx Submits Expanded Access Treatment Protocol to FDA for Implantable Biodegradable Naltrexone Pellet for Opioid Use Disorder Treatment
Company hopes in 30 days to begin making its drug candidate available to help patients and address public health crisis….
Ketabon GmbH Reports Top-Line Results From Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
Ketabon, a joint venture between HMNC Brain Health and Develco Pharma, recently announced top-line results from its Phase 2 KET01-02 Ketabon study with lead asset…
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
PDS Biotechnology Corporation recently announced the submission to the US FDA of an updated Chemistry, Manufacturing and Controls (CMC) package and a Phase 3 multicenter…
Absci & Caltech Join Forces to Accelerate Affordable HIV Therapeutic Vaccine Development
Absci Corporation recently announced leading researchers at the California Institute of Technology (Caltech) in conjunction with Absci, a leader in AI drug creation, received a…
Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics
Clinigen Limited has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on….
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia
GeoVax Labs, Inc. recently announced vaccinations have begun in an investigator-initiated clinical trial (ClinicalTrials.gov Identifier: NCT05672355) of GEO-CM04S1 in patients with chronic lymphocytic leukemia (CLL),…
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial in Individuals With PKU
Jnana Therapeutics recently announced the first participant has been dosed in its Phase 1b clinical trial of JNT-517 in individuals with phenylketonuria (PKU). JNT-517 is…
CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora in Acute Pancreatitis
CalciMedica Inc. recently announced its ongoing CARPO trial, a Phase 2b trial evaluating Auxora for the treatment of acute pancreatitis (AP) with accompanying systemic inflammatory…
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer & Expanded Pfizer Relationship
Cardiff Oncology, Inc. recently announced plans to advance the company’s lead program to the first-line setting of metastatic colorectal cancer (mCRC) and conduct its new CRDF-004 trial with study execution support from Pfizer….
Lisata Therapeutics Announces US FDA Orphan Drug Designation Granted for the Treatment of Malignant Glioma
Lisata Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation to LSTA1, the company’s lead product candidate, for the treatment of malignant…
Recursion Bridges the Protein & Chemical Space With Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion recently announced it has successfully screened the Enamine REAL Space chemical library using its MatchMaker technology, recently acquired from Cyclica, to predict the protein target(s) for….
Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore Platform
Comera Life Sciences Holdings, Inc. recently announced a significant expansion of its SQore patent portfolio with the issuance of four new patents and two new…
Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders
Silo Pharma, Inc. recently announced it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in….
